Research

New findings, and what they do and do not show.

The Alzheimer's risk gene that clogs the brain's wire wrappers

An MIT team knocked out every protein-coding gene, one at a time, in human oligodendrocytes carrying APOE4. The trail led to Wnt signaling, an enzyme called GSK3B, and fat droplets where insulation should be. It led there in dishes, organoids and mice, and in no patient yet.

A Blood Test for Alzheimer's Tracks Amyloid the Same Way Across Groups, Even Though Its Starting Numbers Differ

In a JAMA Neurology study of more than 15,000 people screened for an Alzheimer's prevention trial, a blood marker called percent p-tau217 rose and fell with brain amyloid in roughly the same pattern for Asian, Black, White, Hispanic and non-Hispanic participants. Their baseline levels of that same marker, though, were not identical: they ran lower in Asian, Black and Hispanic participants than in White and non-Hispanic participants.

One ruler, 18 countries: the world's new dementia cases, counted the same way at last

Pooling participant-level data on 38,418 people from 22 population-based cohorts in 18 countries, researchers put the number of people who developed dementia worldwide in 2023 at 11.4 million, and project 24.7 million new cases a year by 2050. Rates ran higher in women and in lower-income countries. Published in JAMA Neurology on October 12, 2026.

A Machine Learns to Pick Amyloid's Signal Out of the Noise of Aging

Trained on resting state scans from 289 older adults, a contrastive deep learning model pulled apart two tangled signals in the aging brain: one shared by everyone growing old, one specific to amyloid buildup. The amyloid signal tracked with attention and memory scores.

Two Years Earlier, a Third More Value: What a New Alzheimer's Model Found

Researchers at the USC Schaeffer Center built a computer model of a population like the one in donanemab's pivotal trial, then asked what changes if treatment starts earlier. Their answer: $104,900 in projected lifetime value per patient, climbing 32 percent with a two year head start, and a bigger share of costs offset by lower Medicaid spending.

Thirty-Year US Death Data Give Parkinson's Mortality a Forward Projection to 2030

A national review of 1.15 million Parkinson's-related death certificates filed from 1999 through 2025 finds that the overall age-adjusted mortality rate did not change significantly over the full period, and that most of the apparent decline since 2021 traces to the fading effect of COVID-19 being listed alongside Parkinson's on death certificates, not to any improvement in underlying mortality.

Antibody Targeting a Sugar-Binding Immune Protein Advances to Phase 2 in Parkinson's Disease

TrueBinding's TB006, an antibody against galectin-3, has entered a placebo-controlled Phase 2a trial in early Parkinson's disease, according to its federal registration. The approach targets neuroinflammation rather than the alpha-synuclein clumping or kinase pathways most late-stage Parkinson's drugs pursue, and no human efficacy data in Parkinson's disease exist yet.

Head-to-Head Trial Finds Two Tau PET Scans Do Not Always Agree

A multicentre trial that scanned the same 682 people with two tau PET tracers found the scans agreed on tau status most of the time but disagreed often enough to change who would count as tau-positive, a distinction that can decide trial eligibility and treatment access. Researchers say the finding does not tell them which tracer is right, since no independent test of tau in a living brain exists to check either one against.

An enzyme called IDOL, and the receptors it throws away

Indiana University researchers report that deleting the Idol gene from neurons in a mouse model of Alzheimer's left far less amyloid in the cortex, and lifted a set of receptors that handle the brain's fats. It is mouse work, and it is a target, not a treatment.

Brazil's prion cases are notifiable. Only some of them get counted.

A new Frontiers in Neuroscience analysis of 17 years of Brazilian Ministry of Health records finds 1,576 suspected Creutzfeldt-Jakob notifications where the authors calculate about 3,200 cases should have occurred. A Mexico City emergency department series points the same way from the opposite direction.

CJD mutation left mice open to pure prion protein fibrils

In a mouse study published on 5 February 2026 in the Journal of General Virology, cofactor-free prion protein fibrils induced misfolded protein and spongiform brain damage in knock-in animals carrying the E200K mutation, but not in animals with wild-type prion protein.